July 21, 2016
The state stem cell agency, the California Institute for Regenerative Medicine (CIRM), today approved a $1.1 million grant to UC Davis for research aimed at developing a treatment for Angelman syndrome, a rare, neurogenetic autism-spectrum disorder that occurs in one in 15,000 live births.
May 31, 2016
Ralph de Vere White, a beloved urologist and acclaimed researcher who led the UC Davis Comprehensive Cancer to designation by the National Cancer Institute (NCI), steps down as its long-time director on June 29.
May 17, 2016
The National Cancer Institute (NCI) has re-designated the UC Davis Comprehensive Cancer Center “comprehensive,” meaning that it meets stringent criteria in the areas of laboratory, clinical and population-based research, professional and public education and in the dissemination of clinical and public advances to the communities it serves.
April 28, 2016
In a study published today in Cell Reports, Wenbin Deng and his colleagues present data showing that immature astroglial transplants, derived from human-induced pluripotent stem cells (iPSCs), are highly protective against white matter brain injury — which can occur from lack of oxygen following a stroke or in childbirth — and can improve spatial learning and memory function in mouse models.
April 25, 2016
As part of a new multicenter clinical trial, UC Davis Health System researchers will test whether a novel stem cell treatment can reduce the pain and mobility issues caused by degenerative disc disease.
March 21, 2016
Two new UC Davis research efforts, one aimed at addressing fatal early childhood conditions known as Tay-Sachs and Sandhoff disease, the other designed to develop an immunotherapy that would eradicate solid tumor cancer stem cells and create sustained anti-tumor effects, have been approved for funding by the California Institute for Regenerative Medicine (CIRM).
March 15, 2016
In a promising finding for research into Huntington’s disease (HD) — the devastating inherited neurodegenerative disorder — a team of UC Davis investigators has identified for the first time a way to use human mesenchymal stem cells (MSCs) to deliver the key brain protein growth factor that is dramatically diminished by Huntington’s disease.